Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways

Pulmonary Pharmacology and Therapeutics

Volumn 32, Issue , 2015, Pages 15-23

  Calzetta, Luigino ^a   Cazzola, Mario ^a   Page, Clive P ^b   Rogliani, Paola ^a   Facciolo, Francesco ^c   Matera, Maria Gabriella ^d  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Airway smooth muscle; Asthma; COPD; Glycopyrronium; Human isolated bronchi; Relaxant response; RPL554; Small airways; Synergistic interaction

Indexed keywords

GLYCOPYRRONIUM BROMIDE; PHOSPHODIESTERASE III; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; RPL 554; UNCLASSIFIED DRUG; 9,10-DIMETHOXY-2-(2,4,6-TRIMETHYLPHENYLIMINO)-3-(N-CARBAMOYL-2-AMINOETHYL)-3,4,6,7-TETRAHYDRO-2H-PYRIMIDINO(6,1-A)ISOQUINOLIN-4-ONE; GLYCOPYRRONIUM; ISOQUINOLINE DERIVATIVE; MUSCARINIC RECEPTOR BLOCKING AGENT; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; PYRIMIDINONE DERIVATIVE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ASTHMA; BRONCHODILATATION; BRONCHUS; BRONCHUS MUSCLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; DRUG EFFECT; DRUG POTENTIATION; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN TISSUE; MALE; MIDDLE AGED; PRIORITY JOURNAL; DRUG EFFECTS; ELECTROSTIMULATION; METABOLISM; MUSCLE CONTRACTION; MUSCLE RELAXATION;

AGED; BRONCHI; DRUG SYNERGISM; ELECTRIC STIMULATION; FEMALE; GLYCOPYRROLATE; HUMANS; ISOQUINOLINES; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; MUSCLE CONTRACTION; MUSCLE RELAXATION; PHOSPHODIESTERASE 3 INHIBITORS; PHOSPHODIESTERASE 4 INHIBITORS; PYRIMIDINONES;

EID: 84930510769     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2015.03.007     Document Type: Article

References (60)

1. GOLD Global strategy for the diagnosis, management and prevention of COPD 2014, Global Initiative for Chronic Obstructive Lung Disease (GOLD), Updated 2014, (Last accessed September 2014). http://www.goldcopd.org/.
2. GINA Global Initiative for Asthma. Guidelines: global strategy for asthma management and prevention (GINA) 2011, Available from:, (Last accessed January 31, 2015). http://www.ginasthma.com./.
3. Griffiths B., Ducharme F.M. Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. Paediatr. Respir. Rev. 2013, 14:234-235.
4. Rodrigo G.J., Castro-Rodriguez J.A. Anticholinergics in the treatment of children and adults with acute asthma: a systematic review with meta-analysis. Thorax 2005, 60:740-746.
5. van der Molen T., Cazzola M. Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. Prim. Care Respir. J. 2012, 21:101-108.
6. Cazzola M., Calzetta L., Segreti A., Facciolo F., Rogliani P., Matera M.G. Translational study searching for synergy between glycopyrronium and indacaterol. COPD - J. Chronic Obstr. Pulm. Dis. 2014, 1-7. 10.3109/15412555.2014.922172.
7. Cazzola M., Calzetta L., Page C.P., Rogliani P., Facciolo F., Gavalda A., et al. Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi. Eur. J. Pharmacol. 2014, 745:135-143.
8. Suissa S., Patenaude V., Lapi F., Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax 2013, 68:1029-1036.
9. Magnussen H., Disse B., Rodriguez-Roisin R., Kirsten A., Watz H., Tetzlaff K., et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N. Engl. J. Med. 2014, 371:1285-1294.
10. Cazzola M., Lopez-Campos J.L., Puente-Maestu L. The MABA approach: a new option to improve bronchodilator therapy. Eur. Respir. J. 2013, 42:885-887.
11. Franciosi L.G., Diamant Z., Banner K.H., Zuiker R., Morelli N., Kamerling I.M., et al. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials. Lancet Respir. Med. 2013, 1:714-727.
12. Calzetta L., Page C.P., Spina D., Cazzola M., Rogliani P., Facciolo F., et al. Effect of the mixed phosphodiesterase 3/4 inhibitor RPL554 on human isolated bronchial smooth muscle tone. J. Pharmacol. Exp. Ther. 2013, 346:414-423.
13. Calzetta L., Cazzola M., Page C.P., Rogliani P., Facciolo F., Matera M.G. Interaction between RPL554 and glycopyrronium bromide in small human airways. Abstract P3337. ERS International Congress. Munich, Germany 2014.
14. Calzetta L., Cazzola M., Page C.P., Rogliani P., Facciolo F., Matera M.G. Long-lasting interaction study between RPL554 and glycopyrronium bromide on human isolated bronchi. Abstract P3334. ERS International Congress. Munich, Germany 2014.
15. van Lunteren E., Moyer M. Auxotonic contractile responses of rat tracheal and bronchial airway smooth muscle. Pulm. Pharmacol. Ther. 2001, 14:443-453.
16. Wohlsen A., Uhlig S., Martin C. Immediate allergic response in small airways. Am. J. Respir. Crit. Care Med. 2001, 163:1462-1469.
17. Calzetta L., Rogliani P., Cazzola M., Matera M.G. Advances in asthma drug discovery: evaluating the potential of nasal cell sampling and beyond. Expert Opin. Drug Discov. 2014, 9:595-607.
18. Freas W., Hart J.L., Golightly D., McClure H., Muldoon S.M. Contractile properties of isolated vascular smooth muscle after photoradiation. Am. J. Physiol. 1989, 256:H655-H664.
19. Hatake K., Wakabayashi I. Ethanol suppresses L-arginine-induced relaxation response of rat aorta stimulated with bacterial lipopolysaccharide. Nihon Arukoru Yakubutsu Igakkai Zasshi 2000, 35:61-68.
20. Motulsky H., Christopoulos A. Fitting models to biological data using linear and nonlinear regression: a practical guide to curve fitting 2004, Oxford University Press, Oxford.
21. Calzetta L., Spina D., Cazzola M., Page C.P., Facciolo F., Rendina E.A., et al. Pharmacological characterization of adenosine receptors on isolated human bronchi. Am. J. Respir. Cell. Mol. Biol. 2011, 45:1222-1231.
22. Boik J.C., Newman R.A., Boik R.J. Quantifying synergism/antagonism using nonlinear mixed-effects modeling: a simulation study. Stat. Med. 2008, 27:1040-1061.
23. Boucher A.N., Tam V.H. Mathematical formulation of additivity for antimicrobial agents. Diagn. Microbiol. Infect. Dis. 2006, 55:319-325.
24. Goldoni M., Johansson C. A mathematical approach to study combined effects of toxicants in vitro: evaluation of the Bliss independence criterion and the Loewe additivity model. Toxicol. In Vitro 2007, 21:759-769.
25. Greco W.R., Bravo G., Parsons J.C. The search for synergy: a critical review from a response surface perspective. Pharmacol. Rev. 1995, 47:331-385.
26. Lee S.I. Drug interaction: focusing on response surface models. Korean J. Anesthesiol. 2010, 58:421-434.
27. Meletiadis J., Mouton J.W., Meis J.F., Verweij P.E. In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob. Agents Chemother. 2003, 47:106-117.
28. Cazzola M., Calzetta L., Rogliani P., Lauro D., Novelli L., Page C.P., et al. High glucose enhances responsiveness of human airways smooth muscle via the Rho/ROCK pathway. Am. J. Respir. Cell. Mol. Biol. 2012, 47:509-516.
29. Cazzola M., Calzetta L., Page C.P., Rinaldi B., Capuano A., Matera M.G. Protein prenylation contributes to the effects of LPS on EFS-induced responses in human isolated bronchi. Am. J. Respir. Cell. Mol. Biol. 2011, 45:704-710.
30. Matera M.G., Calzetta L., Sanduzzi A., Page C.P., Cazzola M. Effects of neuraminidase on equine isolated bronchi. Pulm. Pharmacol. Ther. 2008, 21:624-629.
31. Matera M.G., Calzetta L., Peli A., Scagliarini A., Matera C., Cazzola M. Immune sensitization of equine bronchus: glutathione, IL-1beta expression and tissue responsiveness. Respir. Res. 2005, 6:104.
32. Rogliani P., Calzetta L., Rendina E.A., Massullo D., Dauri M., Rinaldi B., et al. The influence of propofol, remifentanil and lidocaine on the tone of human bronchial smooth muscle. Pulm. Pharmacol. Ther. 2013, 26:325-331.
33. Matera M.G., Calzetta L., Passeri D., Facciolo F., Rendina E.A., Page C., et al. Epithelium integrity is crucial for the relaxant activity of brain natriuretic peptide in human isolated bronchi. Br. J. Pharmacol. 2011, 163:1740-1754.
34. Haddad E.B., Patel H., Keeling J.E., Yacoub M.H., Barnes P.J., Belvisi M.G. Pharmacological characterization of the muscarinic receptor antagonist, glycopyrrolate, in human and guinea-pig airways. Br. J. Pharmacol. 1999, 127:413-420.
35. Boswell-Smith V., Spina D., Oxford A.W., Comer M.B., Seeds E.A., Page C.P. The pharmacology of two novel long-acting phosphodiesterase 3/4 inhibitors, RPL554 [9,10-dimethoxy-2(2,4,6-trimethylphenylimino)-3-(n-carbamoyl-2-aminoethyl) -3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565 [6,7-dihydro-2-(2,6-diisopropylphenoxy)-9,10-dimethoxy-4H-pyrimido[6,1-a]i soquinolin-4-one]. J. Pharmacol. Exp. Ther. 2006, 318:840-848.
36. Cazzola M., Page C.P., Calzetta L., Matera M.G. Emerging anti-inflammatory strategies for COPD. Eur. Respir. J. 2012, 40:724-741.
37. Myou S., Fujimura M., Kamio Y., Ishiura Y., Tachibana H., Hirose T., et al. Bronchodilator effect of inhaled olprinone, a phosphodiesterase 3 inhibitor, in asthmatic patients. Am. J. Respir. Crit. Care Med. 1999, 160:817-820.
38. Schudt C., Tenor H., Hatzelmann A. PDE isoenzymes as targets for anti-asthma drugs. Eur. Respir. J. 1995, 8:1179-1183.
39. Boswell-Smith V., Cazzola M., Page C.P. Are phosphodiesterase 4 inhibitors just more theophylline?. J. Allergy Clin. Immunol. 2006, 117:1237-1243.
40. Calverley P.M., Rabe K.F., Goehring U.M., Kristiansen S., Fabbri L.M., Martinez F.J. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009, 374:685-694.
41. Spina D., Matera G.M., Riccio M.M., Page C.P. A comparison of sensory nerve function in human, guinea-pig, rabbit and marmoset airways. Life Sci. 1998, 63:1629-1642.
42. Linden A. NANC neural control of airway smooth muscle tone. Gen. Pharmacol. 1996, 27:1109-1121.
43. Barnes P.J. Neural control of human airways in health and disease. Am. Rev. Respir. Dis. 1986, 134:1289-1314.
44. Kirchmair R., Marksteiner J., Troger J., Mahata S.K., Mahata M., Donnerer J., et al. Human and rat primary C-fibre afferents store and release secretoneurin, a novel neuropeptide. Eur. J. Neurosci. 1994, 6:861-868.
45. Matera M.G., Calzetta L., Segreti A., Cazzola M. Emerging drugs for chronic obstructive pulmonary disease. Expert Opin. Emerg. Drugs 2012, 17:61-82.
46. Kamikawa Y. Neurogenic control of airway smooth muscle function. J. Pharmacol. Toxicol. Methods 1994, 31:207-213.
47. Villetti G., Bergamaschi M., Bassani F., Bolzoni P.T., Harrison S., Gigli P.M., et al. Pharmacological assessment of the duration of action of glycopyrrolate vs tiotropium and ipratropium in guinea-pig and human airways. Br. J. Pharmacol. 2006, 148:291-298.
48. Binks A.P., Paydarfar D., Schachter S.C., Guz A., Banzett R.B. High strength stimulation of the vagus nerve in awake humans: a lack of cardiorespiratory effects. Respir. Physiol. 2001, 127:125-133.
49. Myers A.C. Transmission in autonomic ganglia. Respir. Physiol. 2001, 125:99-111.
50. Schleputz M., Uhlig S., Martin C. Electric field stimulation of precision-cut lung slices. J. Appl. Physiol. 2011, 110:545-554.
51. Schleputz M., Rieg A.D., Seehase S., Spillner J., Perez-Bouza A., Braunschweig T., et al. Neurally mediated airway constriction in human and other species: a comparative study using precision-cut lung slices (PCLS). PLoS One 2012, 7:e47344.
52. Belvisi M.G. Overview of the innervation of the lung. Curr. Opin. Pharmacol. 2002, 2:211-215.
53. Canning B.J., Fischer A. Neural regulation of airway smooth muscle tone. Respir. Physiol. 2001, 125:113-127.
54. Kummer W., Lips K.S. Non-neuronal acetylcholine release and its contribution to COPD pathology. Drug Discov. Today Dis. Mech. 2006, 3:47-52.
55. Kummer W., Lips K.S., Pfeil U. The epithelial cholinergic system of the airways. Histochem. Cell. Biol. 2008, 130:219-234.
56. Wessler I., Kirkpatrick C.J. Acetylcholine beyond neurons: the non-neuronal cholinergic system in humans. Br. J. Pharmacol. 2008, 154:1558-1571.
57. Kanazawa H., Kawaguchi T., Shoji S., Fujii T., Kudoh S., Hirata K., et al. Synergistic effect of nitric oxide and vasoactive intestinal peptide on bronchoprotection against histamine in anesthetized guinea pigs. Am. J. Respir. Crit. Care Med. 1997, 155:747-750.
58. Palmer L.S., Valcic M., Melman A., Giraldi A., Wagner G., Christ G.J. Characterization of cyclic AMP accumulation in cultured human corpus cavernosum smooth muscle cells. J. Urol. 1994, 152:1308-1314.
59. Tanaka T., Ishikawa T., Hagiwara M., Onoda K., Itoh H., Hidaka H. Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle. Pharmacology 1988, 36:313-320.
60. Sturton G., Persson C., Barnes P.J. Small airways: an important but neglected target in the treatment of obstructive airway diseases. Trends Pharmacol. Sci. 2008, 29:340-345.